VAERS Explorer
Back to explore

Report #2871175

Received Nov 6, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
5 yrs
State
TX
Recovered
Unknown
Vaccinated
Oct 27, 2025
Onset
Oct 27, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
IPVPOLIO VIRUS, INACT. (IPOL)SANOFI PASTEURUNKY1D03P1OT / LA

Symptoms (2)

No adverse eventWrong patient

Symptom narrative

medication error (unintentional) due to IPOL being accidentally administered to the wrong patient with no reported adverse event; Initial information received on 28-Oct-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case is linked to US-SA-2025SA324471 (Cluster case). This case involves a 5 years old female patient who had medication error (unintentional) due to IPV (VERO) [IPOL] being accidentally administered with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included MEASLES VACCINE LIVE (ENDERS-EDMONSTON), MUMPS VACCINE LIVE (JERYL LYNN), RUBELLA VACCINE LIVE (WISTAR RA 27/3), VARICELLA ZOSTER VACCINE LIVE (OKA/MERCK) (PROQUAD) for Immunisation. On 27-Oct-2025, the patient accidently received a 0.5 ml (frequency: once) dose of suspect IPV (VERO) Suspension for injection (lot Y1D03P1, Expiry: 31-Aug-2027, strength: standard) via intramuscular route in the left arm as Immunization which was medication error (unintentional) with no reported adverse event (wrong patient received product) (Latency: same day). Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments: US-SA-2025SA324471:

Other medications

PROQUAD